Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.
about
Ionotropic GABA receptor antagonism-induced adverse outcome pathways for potential neurotoxicity biomarkersSupporting read-across using biological dataA Workflow to Investigate Exposure and Pharmacokinetic Influences on High-Throughput in Vitro Chemical Screening Based on Adverse Outcome PathwaysScreening Chemicals for Receptor-Mediated Toxicological and Pharmacological Endpoints: Using Public Data to Build Screening Tools within a KNIME Workflow.Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical ResearchCritical Factors in the Assessment of Cholestatic Liver Injury In Vitro.Building shared experience to advance practical application of pathway-based toxicology: liver toxicity mode-of-action.Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.Validation of precision-cut liver slices to study drug-induced cholestasis: a transcriptomics approach.Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.Limitations of toxicity characterization in life cycle assessment: Can adverse outcome pathways provide a new foundation?A shift in paradigm towards human biology-based systems for cholestatic-liver diseases."Watching the Detectives" report of the general assembly of the EU project DETECTIVE Brussels, 24-25 November 2015.Adverse outcome pathway development from protein alkylation to liver fibrosis.Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.In Silico Prediction of Organ Level Toxicity: Linking Chemistry to Adverse Effects.Rat precision-cut liver slices predict drug-induced cholestatic injury.Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes.Adverse outcome pathways: hype or hope?Application of in silico and in vitro methods in the development of adverse outcome pathway constructs in wildlife.Modern methodologies and tools for human hazard assessment of chemicalsHepatotoxic combination effects of three azole fungicides in a broad dose range.AOP-DB: A database resource for the exploration of Adverse Outcome Pathways through integrated association networks.Omics-based responses induced by bosentan in human hepatoma HepaRG cell culturesSystems Biology and Synthetic Biology: A New Epoch for Toxicology Research
P2860
Q26778336-D538959D-8E7D-4AC6-9333-D5513019605EQ28834626-9F4AA180-9D50-4119-B92C-3252EEBBEF97Q30044590-864221B8-DE47-4AB6-A964-11C976E06C08Q30489654-9E08CFB6-DE6B-4BDA-9129-324428AE3E09Q33703437-8FB0FCD9-DB10-452B-A455-B89413CA609AQ36239384-5619E574-937D-4CF1-80CA-D9599767BAA7Q36614256-29F81EE6-AF5A-4379-AE78-9E7F0D4DD1C7Q36655325-C11C69D2-698E-46C4-BECC-3D65CCEF5E19Q37590883-B511B7C4-B1E8-44C2-8F15-1BB34D57A81EQ37651374-7753FAD1-BBC7-4DBE-A151-C4794B603973Q38539524-C07F3148-7EFA-455D-965E-19453DE108CBQ38578965-0C00E2C2-4D7A-41D8-B8AF-C0F323782E94Q38595049-7018058D-2791-4F2C-8ED4-3ADDE60DF4AEQ38873791-D4AB1D1E-3AAC-4970-BDB5-43D9DA4DB9EEQ38932043-36D31CC6-F621-4D93-BC54-6B42EF822AC7Q39182452-A1F1449E-1C76-4CE0-83EF-019B37FA9EA3Q39458432-59F77A59-AAEA-478E-AB29-925A29A0E901Q42362293-D095B61F-18A6-482A-B2EA-D93F0DAB7875Q42379819-357781BC-1196-4894-8E33-51C80596EF96Q42697287-D50E07F8-31C3-4668-86E2-27D4818AA00CQ42967667-301879AF-B0F6-46A9-AE40-D4592ED27D7CQ47154406-E80B0EA9-4243-4A02-A422-3EDCDCC41CA4Q48177885-74CBBCBC-ABC7-4D78-A8F6-AA9F5F445D71Q49904301-8654C079-7A6E-49CB-BB5B-A389E9B06E34Q57119333-33D32C3A-A6FB-4C4B-906A-E856A0766C6FQ59103406-F1F6E02F-38C2-4EC8-A4B8-C92F3B132DD8
P2860
Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Development of an adverse outc ...... n to cholestatic liver injury.
@en
Development of an adverse outc ...... n to cholestatic liver injury.
@nl
type
label
Development of an adverse outc ...... n to cholestatic liver injury.
@en
Development of an adverse outc ...... n to cholestatic liver injury.
@nl
prefLabel
Development of an adverse outc ...... n to cholestatic liver injury.
@en
Development of an adverse outc ...... n to cholestatic liver injury.
@nl
P2093
P2860
P50
P356
P1476
Development of an adverse outc ...... n to cholestatic liver injury.
@en
P2093
Brigitte Landesmann
Catherine Willett
Hartmut Jaeschke
Maurice Whelan
Stefanie Vinken
Vera Rogiers
P2860
P304
P356
10.1093/TOXSCI/KFT177
P577
2013-08-14T00:00:00Z